RT Journal Article SR Electronic T1 Existence of SARS-CoV-2 RNA on ambient particulate matter samples: A nationwide study in Turkey JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.01.24.21250391 DO 10.1101/2021.01.24.21250391 A1 Özgecan Kayalar A1 Akif Arı A1 Gizem Babuççu A1 Nur Konyalılar A1 Özlem Doğan A1 Füsun Can A1 Ülkü A. Şahin A1 Eftade O. Gaga A1 S. Levent Kuzu A1 Pelin E. Arı A1 Mustafa Odabası A1 Yücel Taşdemir A1 S.Sıddık Cindoruk A1 Fatma Esen A1 Egemen Sakın A1 Burak Çalışkan A1 Lokman H. Tecer A1 Merve Fıçıcı A1 Ahmet Altın A1 Burcu Onat A1 Coşkun Ayvaz A1 Burcu Uzun A1 Arslan Saral A1 Tuncay Döğeroğlu A1 Semra Malkoç A1 Özlem Ö. Üzmez A1 Fatma Kunt A1 Senar Aydın A1 Melik Kara A1 Barış Yaman A1 Güray Doğan A1 Bihter Olgun A1 Ebru N. Dokumacı A1 Gülen Güllü A1 Elif S. Uzunpınar A1 Hasan Bayram YR 2021 UL http://medrxiv.org/content/early/2021/02/04/2021.01.24.21250391.abstract AB Coronavirus disease 2019 (COVID-19) is caused by the SARS-CoV-2 virus and has been affecting the world since the end of 2019. Turkey is severely affected with the first case being reported on March 11th 2020. Ambient particulate matter (PM) samples in various size ranges were collected from 13 sites including urban and urban background locations and hospital gardens in 10 cities across Turkey between the 13th of May and the 14th of June, 2020 to investigate a possible presence of SARS-CoV-2 RNA on ambient PM. A total of 155 daily samples (TSP, n=80; PM2.5, n=33; PM2.5-10, n=23; PM10, n=19; and 6 size segregated, n=48) were collected using various samplers in each city. The N1 gene and RdRP gene expressions were analyzed for the presence of SARS-CoV-2 as suggested by the Centers for Disease Control and Prevention (CDC). According to RT-PCR and 3D-RT-PCR analysis, dual RdRP and N1 gene positivity were detected in 20 (9.8 %) of the samples. The highest percentage of virus detection on PM samples was from hospital gardens in Tekirdağ, Zonguldak, and İstanbul—especially in PM2.5 mode. Samples collected from two urban sites were also positive. Findings of this study have suggested that SARS-CoV-2 may be transported by ambient particles especially at sites close to the infection hot-spots. However, whether this has an impact on the spread of the virus infection remains to be determined.Significance Statement Although there are several studies reporting the existence of SARS-CoV-2 in indoor aerosols is established, it remains unclear whether the virus is transported by ambient atmospheric particles. The presence of the SARS-CoV-2 RNA in ambient particles collected from characteristic sites within various size ranges was investigated, and positive results were found in urban sites especially around Turkish hospitals. In this context, this study offers a new discussion on the transmission of the virus via ambient particles.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors thank Koc University Research Center for Translational Medicine (KUTTAM) for funding the laboratory analysis of SARS-CoV-2 in PM samples. The authors thank to officials of Zonguldak Bulent Ecevit University Science and Technology Research Center, and Health Medical Research and Application Center for device support and workforce support during the sampling studies. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:It is a work that does not require ethical permission.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript can be available citing the manuscript.